Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRN-003
- Development stage
- Preclinical
- Lead developer
- Turn Biotechnologies
- Modality
- Vaccines & Immunotherapeutics, Small Molecules
- Administration
- Ophthalmic
01
Overview
TRN-003 is an investigational RNA interference (RNAi) drug being developed by Turn Biotechnologies for the treatment of glaucoma. It is designed as a formulation to address eye diseases, specifically targeting glaucoma, and is currently in preclinical development. The mechanism of action involves RNA interference, which allows for the silencing of specific gene expression related to disease pathology[1][2].
Beyond the preview
Go deeper on TRN-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRN-003.